{
  "meta": {
    "title": "40_Pharmacodynamics",
    "url": "https://brainandscalpel.vercel.app/40-pharmacodynamics-0fd18334.html",
    "scrapedAt": "2025-11-30T06:59:57.620Z"
  },
  "questions": [
    {
      "id": 66316,
      "choices": [
        {
          "id": 277077,
          "text": "Ritonavir"
        },
        {
          "id": 277078,
          "text": "Digoxin"
        },
        {
          "id": 277079,
          "text": "Rifampicin"
        },
        {
          "id": 277080,
          "text": "Morphine"
        }
      ],
      "text": "Following drug is an inhibitor and inducer of P Glycoprotein",
      "unique_key": "Q3462462",
      "question_audio": null,
      "question_video": null,
      "map_id": 34939390,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Ritonavir Ritonavir is a potent inhibitor and inducer of P-glycoprotein (P-gp), a membrane transporter that plays a key role in drug absorption, distribution, and excretion. As a P-gp inhibitor, Ritonavir can increase the bioavailability of other drugs that are substrates of P-gp by reducing their efflux from cells. This is why it is often used as a pharmacokinetic enhancer in combination with other protease inhibitors (e.g., Lopinavir, Atazanavir) to increase their plasma concentrations. However, Ritonavir can also act as a P-gp inducer with prolonged use, leading to enhanced drug clearance and reduced efficacy of P-gp substrates. This dual effect—initial inhibition followed by induction—makes Ritonavir unique compared to other P-gp modulators. Incorrect Options: B) Digoxin – Incorrect Digoxin is not an inhibitor or inducer of P-glycoprotein, but rather a substrate of P-gp. Its transport by P-gp affects its absorption and elimination. When co-administered with P-gp inhibitors (e.g., Ritonavir or Verapamil), digoxin levels increase, leading to potential toxicity. However, Digoxin itself does not modulate P-gp activity. C) Rifampicin – Incorrect Rifampicin is a strong inducer of P-glycoprotein, meaning it enhances the efflux of drugs transported by P-gp, reducing their bioavailability. However, it does not inhibit P-gp. This property leads to increased clearance and reduced plasma levels of P-gp substrates like Digoxin and certain protease inhibitors. Since it lacks an inhibitory effect, Rifampicin is not the correct answer. D) Morphine – Incorrect Morphine is not a significant inducer or inhibitor of P-glycoprotein. While it is a P-gp substrate, its transport across the blood-brain barrier is affected by P-gp activity. However, Morphine does not play a regulatory role in P-gp function, making it incorrect in this context.",
      "correct_choice_id": 277077,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52826341700309942/52826341700309942.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52826341700309942/52826341700309942.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66317,
      "choices": [
        {
          "id": 277081,
          "text": "Acetazolamide: Carbonic anhydrase"
        },
        {
          "id": 277082,
          "text": "Carbidopa: Dopa decarboxylase"
        },
        {
          "id": 277083,
          "text": "Moclobemide: MAO-A"
        },
        {
          "id": 277084,
          "text": "Captopril: Angiotensin converting enzyme (ACE)"
        }
      ],
      "text": "Following are examples of competitive enzyme inhibition except",
      "unique_key": "Q2934459",
      "question_audio": null,
      "question_video": null,
      "map_id": 34958776,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Acetazolamide: Carbonic anhydrase Acetazolamide is a non-competitive inhibitor of carbonic anhydrase. It binds to the enzyme at a site different from the active site, reducing its activity without directly competing with the substrate (CO2 and H2O). As a result, it decreases the formation of carbonic acid (H2CO2), leading to increased excretion of bicarbonate (HCO3-) in urine. This mechanism is utilized in glaucoma, altitude sickness, and metabolic alkalosis. Because acetazolamide does not compete with the substrate for the active site, it is not an example of competitive inhibition, making it the correct answer to this \"EXCEPT\" question. Incorrect Options: B) Carbidopa: Dopa decarboxylase – Correct (Competitive Inhibitor) Carbidopa is a competitive inhibitor of dopa decarboxylase, the enzyme responsible for converting levodopa to dopamine in peripheral tissues. It competes with levodopa for the enzyme's active site, thereby preventing premature peripheral conversion of levodopa before it reaches the brain. This allows more levodopa to cross the blood-brain barrier, enhancing its therapeutic effect in Parkinson’s disease. Because carbidopa directly competes with levodopa at the enzyme's active site, it is a competitive inhibitor. C) Moclobemide: MAO-A – Correct (Competitive Inhibitor) Moclobemide is a reversible, competitive inhibitor of monoamine oxidase-A (MAO-A), an enzyme responsible for the breakdown of serotonin, norepinephrine, and dopamine. By competing for the enzyme’s active site, moclobemide prevents neurotransmitter degradation, leading to increased levels in the brain. This mechanism makes it useful as an antidepressant (RIMA – Reversible Inhibitor of MAO-A). Since moclobemide competes with neurotransmitters for MAO-A, it is a competitive inhibitor. D) Captopril: Angiotensin-Converting Enzyme (ACE) – Correct (Competitive Inhibitor) Captopril is a competitive inhibitor of angiotensin-converting enzyme (ACE). It binds to the active site of ACE, preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This results in vasodilation, reduced blood pressure, and decreased aldosterone secretion, making captopril effective in hypertension and heart failure. Since captopril directly competes with angiotensin I for ACE, it is classified as a competitive inhibitor.",
      "correct_choice_id": 277081,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51819681700310035/51819681700310035.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51819681700310035/51819681700310035.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66318,
      "choices": [
        {
          "id": 277085,
          "text": "Noncompetitive antagonism"
        },
        {
          "id": 277086,
          "text": "Competitive agonism"
        },
        {
          "id": 277087,
          "text": "Competitive antagonism"
        },
        {
          "id": 277088,
          "text": "Noncompetitive agonism"
        }
      ],
      "text": "Parallel rightward shift of agonist DRC is seen in",
      "unique_key": "Q8238710",
      "question_audio": null,
      "question_video": null,
      "map_id": 34664564,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Competitive antagonism A parallel rightward shift of the dose-response curve (DRC) of an agonist is a characteristic feature of competitive antagonism. In competitive antagonism, the antagonist binds reversibly to the same receptor site as the agonist, preventing the agonist from exerting its effect. However, increasing the concentration of the agonist can overcome this antagonism by displacing the antagonist from the receptor. This results in: Rightward shift of the DRC (higher agonist concentration needed to achieve the same response). No change in the maximum response (Emax) because the inhibition can be reversed by increasing agonist concentration. Increase in the EC50 (higher concentration of agonist required to produce 50% of the maximum response). A classic example of competitive antagonism is atropine vs. acetylcholine at muscarinic receptors or propranolol vs. adrenaline at β-adrenergic receptors. Incorrect Options: A) Noncompetitive antagonism – Incorrect In noncompetitive antagonism, the antagonist binds to a site different from the agonist’s binding site (allosteric site) and prevents receptor activation. This leads to: Downward shift of the DRC (reduced maximum response, Emax). No significant rightward shift because the agonist cannot outcompete the antagonist, even at high doses. Example: Ketamine blocking NMDA receptors or phenoxybenzamine (irreversible α-blocker) vs. adrenaline. B) Competitive agonism – Incorrect The term competitive agonism is not commonly used in pharmacology. Agonists usually do not compete with each other; instead, they may act on different receptor subtypes (e.g., dopamine on D1 vs. D2 receptors). If two agonists interact at the same receptor, their effects are typically additive or synergistic rather than producing a parallel rightward shift. D) Noncompetitive agonism – Incorrect Noncompetitive agonism is not a well-defined pharmacological concept. If an agonist binds to an allosteric site and enhances receptor function, it is typically called a positive allosteric modulator (PAM) rather than an agonist. Such agents increase agonist potency or enhance maximum response rather than shifting the DRC to the right.",
      "correct_choice_id": 277087,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56638671700310056/56638671700310056.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56638671700310056/56638671700310056.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66319,
      "choices": [
        {
          "id": 277089,
          "text": "Drug dose that produces 50% of maximal effect"
        },
        {
          "id": 277090,
          "text": "Drug concentration that produces 50% of toxic effect"
        },
        {
          "id": 277091,
          "text": "Drug concentration that produces 50% of lethal effect"
        },
        {
          "id": 277092,
          "text": "Drug concentration that produces 50% of maximal effect"
        }
      ],
      "text": "EC50 is",
      "unique_key": "Q5539723",
      "question_audio": null,
      "question_video": null,
      "map_id": 34541297,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Drug concentration that produces 50% of maximal effect EC50 (Effective Concentration 50%) is defined as the drug concentration that produces 50% of the maximum possible effect in a given system. It is an important parameter in pharmacodynamics and helps determine potency—the lower the EC50, the more potent the drug. EC50 is typically measured in in vitro studies, where drug concentration in the medium is controlled. It is plotted on a dose-response curve, where a lower EC50 value means a drug is effective at lower concentrations, making it more potent. EC50 differs from ED50 (Effective Dose 50%), which refers to the dose required to achieve 50% of the desired effect in a population. For example, morphine has a lower EC50 than aspirin, meaning it requires a lower concentration to achieve 50% of its maximal analgesic effect. Incorrect Options: A) Drug dose that produces 50% of maximal effect – Incorrect This definition describes ED50 (Effective Dose 50%), which refers to the dose (not concentration) required to produce 50% of the maximal effect in a population. While related to EC50, ED50 is used in clinical settings, whereas EC50 is used in laboratory studies. B) Drug concentration that produces 50% of toxic effect – Incorrect This describes TC50 (Toxic Concentration 50%), which refers to the concentration of a drug that causes toxicity in 50% of a population or test system. EC50, in contrast, relates to therapeutic effects, not toxicity. C) Drug concentration that produces 50% of lethal effect – Incorrect This refers to LC50 (Lethal Concentration 50%), which is the concentration that causes death in 50% of a test population (used in toxicology studies, particularly with animal models). EC50 is unrelated to lethality.",
      "correct_choice_id": 277092,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3984851700310067/3984851700310067.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3984851700310067/3984851700310067.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66320,
      "choices": [
        {
          "id": 277093,
          "text": "Less respiratory depression even when given at high dose"
        },
        {
          "id": 277094,
          "text": "Decreased affinity to mu receptor"
        },
        {
          "id": 277095,
          "text": "Can be given in opioid dependent patients"
        },
        {
          "id": 277096,
          "text": "None of the above"
        }
      ],
      "text": "About partial agonistic property of Buprenorphine, which of the following is true",
      "unique_key": "Q5640957",
      "question_audio": null,
      "question_video": null,
      "map_id": 34102982,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Less respiratory depression even when given at high dose Buprenorphine is a partial agonist at the mu opioid receptor and an antagonist at the kappa receptor. As a partial agonist, it has a ceiling effect, meaning that after a certain dose, its effect plateaus, even if the dose is increased further. This property is particularly beneficial because: It produces analgesia similar to full opioid agonists like morphine but with reduced risk of respiratory depression, a major cause of opioid-related deaths. Even at high doses, buprenorphine does not cause severe respiratory depression, making it safer than full agonists like fentanyl or heroin. This makes buprenorphine preferable for opioid dependence treatment and pain management, as it provides pain relief while lowering the risk of fatal respiratory suppression. Thus, option A is correct. Incorrect Options: B) Decreased affinity to mu receptor – Incorrect Buprenorphine actually has a very high affinity for the mu opioid receptor, much higher than full agonists like morphine or heroin. This strong binding prevents other opioids from attaching to the receptor, which is why buprenorphine is effective in treating opioid dependence—it blocks the effects of stronger opioids while producing mild opioid effects itself. Therefore, saying it has \"decreased affinity\" is incorrect. C) Can be given in opioid-dependent patients – Incorrect (but partially true) Buprenorphine can be used for opioid dependence treatment, but there is a key consideration: If given to a patient actively using full agonist opioids (like heroin or methadone), buprenorphine can precipitate withdrawal due to its partial agonist properties and high receptor affinity. It is used in opioid substitution therapy, but it must be given only after withdrawal symptoms have begun to avoid precipitating severe withdrawal. Since the statement does not clarify this important detail, it is not entirely correct. D) None of the above – Incorrect Since option A is correct, option D cannot be the right answer.",
      "correct_choice_id": 277093,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64178071700310078/64178071700310078.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64178071700310078/64178071700310078.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66321,
      "choices": [
        {
          "id": 277097,
          "text": "Physiological antagonism"
        },
        {
          "id": 277098,
          "text": "CHEMICAL antagonism"
        },
        {
          "id": 277099,
          "text": "Competitive antagonism"
        },
        {
          "id": 277100,
          "text": "Noncompetitive antagonism"
        }
      ],
      "text": "Elevation of glucose by corticosteroids is counteracted by insulin is an example",
      "unique_key": "Q3554601",
      "question_audio": null,
      "question_video": null,
      "map_id": 34806666,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Physiological antagonism Physiological antagonism occurs when two drugs or substances produce opposite effects through different mechanisms or pathways, rather than directly competing for the same receptor. In this case: Corticosteroids (e.g., cortisol, prednisone) increase blood glucose levels by promoting gluconeogenesis (glucose production in the liver) and reducing glucose uptake by tissues. Insulin, on the other hand, lowers blood glucose by promoting glucose uptake into cells and inhibiting gluconeogenesis. Since insulin and corticosteroids act through different receptors and pathways but produce opposite effects, this is a classic example of physiological antagonism. Unlike competitive or noncompetitive antagonism, where drugs interact at the same receptor, physiological antagonism occurs between two independent physiological systems. Incorrect Options: B) Chemical antagonism – Incorrect Chemical antagonism occurs when two substances interact directly, leading to the inactivation or neutralization of one drug by another. Example: Protamine sulfate neutralizing heparin (a blood thinner) by forming an inactive complex. In this case, insulin does not chemically neutralize corticosteroids; it works through a separate pathway, making this answer incorrect. C) Competitive antagonism – Incorrect Competitive antagonism occurs when two drugs compete for the same receptor site, leading to a rightward shift in the dose-response curve of the agonist. Example: Atropine vs. acetylcholine at muscarinic receptors or naloxone vs. opioids at opioid receptors. Since insulin and corticosteroids act on completely different receptors (insulin receptors vs. glucocorticoid receptors), there is no direct receptor competition, making this incorrect. D) Noncompetitive antagonism – Incorrect Noncompetitive antagonism occurs when a drug irreversibly binds to a receptor or an allosteric site, preventing an agonist from exerting its effect even at higher doses. Example: Phenoxybenzamine (α-blocker) vs. epinephrine at α-adrenergic receptors. Since insulin does not irreversibly inhibit corticosteroid effects but rather counteracts them through a separate mechanism, this is not noncompetitive antagonism.",
      "correct_choice_id": 277097,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54024371700310087/54024371700310087.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54024371700310087/54024371700310087.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66322,
      "choices": [
        {
          "id": 277101,
          "text": "Glucuronidation"
        },
        {
          "id": 277102,
          "text": "Glycine conjugation"
        },
        {
          "id": 277103,
          "text": "Glutathione conjugation"
        },
        {
          "id": 277104,
          "text": "Acetylation"
        }
      ],
      "text": "Which of the following phase II conjugation Enzymes are located at mitochondria",
      "unique_key": "Q2967425",
      "question_audio": null,
      "question_video": null,
      "map_id": 34527031,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Glycine conjugation Glycine conjugation is a Phase II metabolism reaction that occurs in the mitochondria. This process primarily detoxifies aromatic acids (e.g., benzoic acid) and bile acids by conjugating them with glycine to form water-soluble products that can be excreted in the urine. Enzyme involved: Glycine N-acyltransferase (GLYAT) Location: Mitochondria of liver and kidney cells Example reaction: Benzoic acid + glycine ? Hippuric acid (excreted in urine) This reaction is clinically important in cases of sodium benzoate treatment for hyperammonemia, where benzoate is conjugated with glycine to form hippurate, helping to remove nitrogen from the body. Since glycine conjugation is the only Phase II reaction occurring in the mitochondria, option B is correct. Incorrect Options: A) Glucuronidation – Incorrect Glucuronidation is a Phase II reaction catalyzed by UDP-glucuronosyltransferases (UGTs), which attach glucuronic acid to substrates, increasing their solubility. Location: It occurs in the endoplasmic reticulum (ER), not mitochondria. Example: Bilirubin, paracetamol, morphine glucuronidation. Since it does not occur in the mitochondria, this answer is incorrect. C) Glutathione conjugation – Incorrect Glutathione conjugation is mediated by glutathione S-transferases (GSTs) and involves the addition of glutathione (GSH) to toxic substances, making them less harmful and more water-soluble for excretion. Location: Occurs in the cytosol and endoplasmic reticulum (ER), not mitochondria. Example: Detoxification of electrophilic drugs, free radicals, and paracetamol metabolism (via the NAPQI pathway). Since it is not mitochondrial, this option is incorrect. D) Acetylation – Incorrect Acetylation is catalyzed by N-acetyltransferases (NATs) and involves the transfer of an acetyl group to drugs or toxins. Location: Occurs in the cytoplasm, not mitochondria. Example: Acetylation of isoniazid (INH), hydralazine, and sulfonamides. Clinical relevance: \"Slow acetylators\" have a genetic polymorphism leading to drug toxicity. Since acetylation occurs in the cytoplasm, not mitochondria, this option is incorrect.",
      "correct_choice_id": 277102,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66323,
      "choices": [
        {
          "id": 277105,
          "text": "CYP 3A4"
        },
        {
          "id": 277106,
          "text": "CYP 2D9"
        },
        {
          "id": 277107,
          "text": "CYP 2C9"
        },
        {
          "id": 277108,
          "text": "CYP 1A2"
        }
      ],
      "text": "Charcoal-broiled foods and smoking induces following enzyme",
      "unique_key": "Q1617121",
      "question_audio": null,
      "question_video": null,
      "map_id": 34521094,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) CYP1A2 CYP1A2 is a liver enzyme belonging to the cytochrome P450 family, responsible for the metabolism of various drugs and xenobiotics. It is induced by polycyclic aromatic hydrocarbons (PAHs), which are present in charcoal-broiled foods and cigarette smoke. Charcoal-broiled foods contain PAHs, which activate the aryl hydrocarbon receptor (AhR), leading to increased transcription of the CYP1A2 enzyme. Smoking also exposes the body to PAHs, leading to CYP1A2 induction. Drugs metabolized by CYP1A2 include caffeine, theophylline, warfarin, clozapine, and acetaminophen. Clinical relevance: Smokers metabolize CYP1A2 substrates faster, leading to lower drug levels and reduced efficacy (e.g., reduced clozapine and theophylline effectiveness). Stopping smoking reduces CYP1A2 activity, which may lead to higher drug levels and toxicity. Since CYP1A2 is the enzyme induced by charcoal-broiled foods and smoking, option D is correct. Incorrect Options: A) CYP3A4 – Incorrect CYP3A4 is the most abundant P450 enzyme in the liver and intestines, responsible for metabolizing nearly 50% of all drugs, including statins, benzodiazepines, and immunosuppressants. Induced by: Rifampin, phenytoin, St. John’s wort, glucocorticoids. Not significantly induced by charcoal-broiled foods or smoking. Since CYP3A4 is not the primary enzyme induced by PAHs, this answer is incorrect. B) CYP2D6 – Incorrect CYP2D6 metabolizes many psychoactive drugs (e.g., codeine, antidepressants, beta-blockers). Not inducible by external factors like smoking or diet. Instead, it shows genetic polymorphism: Some people are poor metabolizers, while others are ultrarapid metabolizers. Since CYP2D6 is not induced by PAHs, this answer is incorrect. C) CYP2C9 – Incorrect CYP2C9 metabolizes drugs such as warfarin, phenytoin, and NSAIDs. Induced by: Rifampin and barbiturates. Not significantly affected by smoking or charcoal-broiled foods. Since CYP2C9 is not the main enzyme induced by PAHs, this option is incorrect.",
      "correct_choice_id": 277108,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15114331700310142/15114331700310142.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15114331700310142/15114331700310142.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66324,
      "choices": [
        {
          "id": 277109,
          "text": "Phase 1 hydrolysis"
        },
        {
          "id": 277110,
          "text": "Phase 1 oxidation"
        },
        {
          "id": 277111,
          "text": "Phase 1 reduction"
        },
        {
          "id": 277112,
          "text": "Phase 1 decyclization"
        }
      ],
      "text": "Desulfuration is an example for",
      "unique_key": "Q9708121",
      "question_audio": null,
      "question_video": null,
      "map_id": 34754078,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Phase 1 Oxidation Desulfuration is a Phase I oxidation reaction in which a sulfur atom is replaced by an oxygen atom in the metabolism of certain drugs and xenobiotics. This reaction is catalyzed by cytochrome P450 enzymes (mainly CYP2C19 and CYP3A4). A classic example of desulfuration occurs in the metabolism of thiopental (a barbiturate), where sulfur (-S) is replaced by oxygen (-O) to form pentobarbital, which has altered pharmacological activity. Another example is parathion metabolism, where it is converted into the active toxic metabolite paraoxon through desulfuration. Since desulfuration involves oxidation of a sulfur-containing compound, it is classified under Phase I oxidation reactions, making option B the correct answer. Incorrect Options: A) Phase 1 Hydrolysis – Incorrect Hydrolysis involves the cleavage of chemical bonds by water, typically affecting esters and amides. Examples: Aspirin (acetylsalicylic acid) hydrolyzed to salicylic acid, procaine hydrolyzed by plasma esterases. Desulfuration does not involve hydrolysis; instead, it involves oxidation. Since desulfuration does not involve hydrolytic cleavage, this answer is incorrect. C) Phase 1 Reduction – Incorrect Reduction reactions involve the gain of electrons or the removal of oxygen, often catalyzed by reductases. Examples: Nitro reduction (Chloramphenicol ? reduced metabolite). Azoreduction (Sulfasalazine ? sulfapyridine + mesalamine). Desulfuration is an oxidation reaction, not a reduction reaction. Since desulfuration adds oxygen instead of removing it, this answer is incorrect. D) Phase 1 Decyclization – Incorrect Decyclization refers to the opening of ring structures during metabolism. Examples: Diazepam metabolism to an open-ring structure. Caffeine metabolism leading to ring cleavage. Desulfuration does not involve breaking a ring structure. Since desulfuration does not involve decyclization, this answer is incorrect.",
      "correct_choice_id": 277110,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27509251700310153/27509251700310153.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27509251700310153/27509251700310153.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66325,
      "choices": [
        {
          "id": 277113,
          "text": "Flavin monooxygenase"
        },
        {
          "id": 277114,
          "text": "Deamination"
        },
        {
          "id": 277115,
          "text": "Amine oxidases"
        },
        {
          "id": 277116,
          "text": "Dehydrogenations"
        }
      ],
      "text": "Following are Cytochrome P450-Independent oxidations except",
      "unique_key": "Q3758420",
      "question_audio": null,
      "question_video": null,
      "map_id": 34528720,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Deamination Deamination refers to the removal of an amine (-NH2) group from a molecule, typically converting amines into ketones or aldehydes. This process is usually catalyzed by cytochrome P450 enzymes, making it a P450-dependent oxidation reaction rather than a P450-independent one. Deamination is commonly seen in the metabolism of amine-containing drugs, such as amphetamine and epinephrine, which undergo oxidation via cytochrome P450 enzymes before excretion. The reaction typically follows this pattern: R-CH2-NH2 → R-CHO + NH3- (formation of an aldehyde and ammonia). Since deamination requires cytochrome P450 enzymes, it is not a P450-independent oxidation, making option B the correct answer. Incorrect Options: A) Flavin Monooxygenase – Incorrect Flavin monooxygenases (FMOs) are a separate class of oxidative enzymes that do not rely on cytochrome P450. They catalyze the oxidation of nitrogen, sulfur, and phosphorus-containing drugs. Example: Metabolism of trimethylamine to trimethylamine N-oxide by FMO3. Since FMOs function independently of cytochrome P450, this option is incorrect. C) Amine Oxidases – Incorrect Amine oxidases, such as monoamine oxidase (MAO) and diamine oxidase (DAO), catalyze the oxidative deamination of amines but do not require cytochrome P450. Example: MAO metabolizes dopamine, serotonin, and norepinephrine. These enzymes are P450-independent, making this option incorrect. D) Dehydrogenations – Incorrect Dehydrogenation involves the removal of hydrogen atoms from a molecule, usually catalyzed by enzymes like alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Example: Ethanol → Acetaldehyde (via alcohol dehydrogenase). Acetaldehyde → Acetic acid (via aldehyde dehydrogenase). These reactions do not require cytochrome P450, making this option incorrect.",
      "correct_choice_id": 277114,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24045931700310163/24045931700310163.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24045931700310163/24045931700310163.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66326,
      "choices": [
        {
          "id": 277117,
          "text": "Enzyme inducer"
        },
        {
          "id": 277118,
          "text": "Enzyme modulator"
        },
        {
          "id": 277119,
          "text": "None"
        },
        {
          "id": 277120,
          "text": "Enzyme inhibitor"
        }
      ],
      "text": "Grapefruit juice is an",
      "unique_key": "Q6443505",
      "question_audio": null,
      "question_video": null,
      "map_id": 34197706,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Enzyme Inhibitor Grapefruit juice is a potent enzyme inhibitor, specifically inhibiting cytochrome P450 3A4 (CYP3A4), an enzyme responsible for the metabolism of many drugs. It contains furanocoumarins, which irreversibly inhibit intestinal CYP3A4, leading to increased drug bioavailability and potential toxicity. Effect on drug metabolism: Drugs that undergo significant first-pass metabolism by CYP3A4 in the gut (e.g., statins, calcium channel blockers, benzodiazepines) experience increased plasma levels when taken with grapefruit juice. This can lead to exaggerated drug effects and toxicity, such as severe hypotension (calcium channel blockers), rhabdomyolysis (statins), and excessive sedation (benzodiazepines). The inhibition is dose-dependent and irreversible, requiring new enzyme synthesis, which can take 24-48 hours to recover. Since grapefruit juice inhibits CYP3A4, leading to increased drug levels and potential toxicity, option D is correct. Incorrect Options: A) Enzyme Inducer – Incorrect Enzyme inducers increase enzyme activity, leading to faster drug metabolism and reduced drug effects. Examples: Rifampin, carbamazepine, phenytoin, St. John’s wort (induce CYP3A4). Grapefruit juice does the opposite—it inhibits CYP3A4 instead of inducing it. Since grapefruit juice does not induce enzymes, this option is incorrect. B) Enzyme Modulator – Incorrect Enzyme modulators can either increase or decrease enzyme activity, depending on the situation. Grapefruit juice is not a modulator but a direct inhibitor of CYP3A4. It does not have a variable or dual action—it consistently inhibits CYP3A4. Since grapefruit juice does not modulate enzyme activity but directly inhibits it, this option is incorrect. C) None – Incorrect Grapefruit juice clearly has an effect on drug metabolism by inhibiting CYP3A4. It is not neutral in its action and can significantly alter drug pharmacokinetics. Since grapefruit juice has a strong inhibitory effect, this option is incorrect.",
      "correct_choice_id": 277120,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44327951700310174/44327951700310174.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44327951700310174/44327951700310174.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66327,
      "choices": [
        {
          "id": 277121,
          "text": "HLA-B *58:01"
        },
        {
          "id": 277122,
          "text": "DRB5 *01:01"
        },
        {
          "id": 277123,
          "text": "HLA-DRB1 *15:01"
        },
        {
          "id": 277124,
          "text": "HLA-B *57:01"
        }
      ],
      "text": "Flucloxacillin-induced liver injury is associated with",
      "unique_key": "Q5104680",
      "question_audio": null,
      "question_video": null,
      "map_id": 34476462,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) HLA-B*57:01 Flucloxacillin-induced liver injury (DILI) is strongly associated with the presence of the HLA-B*57:01 allele. This genetic variant has been identified as a major risk factor for idiosyncratic drug-induced liver injury (DILI) caused by flucloxacillin. Mechanism: Flucloxacillin is metabolized in the liver, and in individuals carrying HLA-B*57:01, the immune system may recognize flucloxacillin-modified peptides as foreign, leading to a T-cell-mediated immune response that results in hepatocellular injury. Clinical Presentation: Flucloxacillin-induced cholestatic hepatitis usually appears 1–6 weeks after drug exposure and may persist for months even after stopping the medication. Genetic Risk: The HLA-B*57:01 allele increases the risk of flucloxacillin-induced liver toxicity by about 80-fold, making it a key genetic marker. Since HLA-B*57:01 is the strongest genetic predictor of flucloxacillin-induced liver injury, option D is correct. Incorrect Options: A) HLA-B*58:01 – Incorrect HLA-B*58:01 is associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). It is not linked to flucloxacillin-induced liver injury. Since HLA-B*58:01 is related to allopurinol hypersensitivity and not flucloxacillin-induced liver injury, this option is incorrect. B) HLA-DRB5*01:01 – Incorrect This allele has been studied in relation to rheumatoid arthritis and multiple sclerosis, but there is no strong evidence linking it to flucloxacillin-induced liver injury. Since HLA-DRB5*01:01 is not associated with flucloxacillin hepatotoxicity, this option is incorrect. C) HLA-DRB1*15:01 – Incorrect HLA-DRB1*15:01 is linked to drug-induced liver injury caused by amoxicillin-clavulanate, but not flucloxacillin. This allele is also associated with multiple sclerosis and other autoimmune diseases. Since HLA-DRB1*15:01 is linked to amoxicillin-clavulanate but not flucloxacillin-induced liver injury, this option is incorrect.",
      "correct_choice_id": 277124,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25883151700310185/25883151700310185.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25883151700310185/25883151700310185.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66328,
      "choices": [
        {
          "id": 277125,
          "text": "Insulin"
        },
        {
          "id": 277126,
          "text": "Salbutamol"
        },
        {
          "id": 277127,
          "text": "Estrogen"
        },
        {
          "id": 277128,
          "text": "Local anesthetics"
        }
      ],
      "text": "Which of the following drugs act through heptahelical (serpentine) receptors",
      "unique_key": "Q1618939",
      "question_audio": null,
      "question_video": null,
      "map_id": 34793382,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Salbutamol acts through heptahelical (serpentine) receptors Heptahelical (serpentine) receptors, also known as G-protein-coupled receptors (GPCRs), are a large family of membrane receptors characterized by their seven transmembrane domains. These receptors mediate signal transduction by interacting with intracellular G-proteins, leading to various physiological effects. Salbutamol is a β2-adrenergic receptor agonist, which belongs to the GPCR family. When salbutamol binds to β2-adrenoceptors, it activates adenylate cyclase via Gs protein, increasing cyclic AMP (cAMP) levels. This results in bronchodilation, making salbutamol useful in treating conditions like asthma and COPD. Thus, salbutamol acts through heptahelical (serpentine) GPCRs, making option B the correct answer. Incorrect Options: A) Insulin – Incorrect Insulin acts via the insulin receptor, which is a tyrosine kinase receptor (RTK), not a GPCR. Upon insulin binding, the receptor undergoes autophosphorylation, activating intracellular signaling pathways like PI3K-AKT and MAP kinase pathways, leading to glucose uptake and metabolic effects. Since insulin does not act through heptahelical receptors, this option is incorrect. C) Estrogen – Incorrect Estrogen binds to intracellular nuclear receptors (estrogen receptors, ERα and ERβ), which are part of the steroid hormone receptor family. These receptors function as transcription factors that regulate gene expression when activated. Since estrogen acts through nuclear receptors and not heptahelical GPCRs, this option is incorrect. D) Local anesthetics – Incorrect Local anesthetics like lidocaine, bupivacaine, and procaine work by blocking voltage-gated sodium (Na+) channels in nerve cells. This prevents action potential propagation, leading to loss of sensation. Since local anesthetics act on ion channels, not GPCRs, this option is incorrect.",
      "correct_choice_id": 277126,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33471191700310491/33471191700310491.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33471191700310491/33471191700310491.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66329,
      "choices": [
        {
          "id": 277129,
          "text": "Intrinsic ion channel operation"
        },
        {
          "id": 277130,
          "text": "Adenylyl cyclase- cyclic AMP pathway"
        },
        {
          "id": 277131,
          "text": "Phospholipase C-IP3: DAG pathway"
        },
        {
          "id": 277132,
          "text": "Nuclear receptor"
        }
      ],
      "text": "Fastest acting receptor/transduction mechanism is",
      "unique_key": "Q9984757",
      "question_audio": null,
      "question_video": null,
      "map_id": 34066687,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Intrinsic ion channel operation Receptors linked to intrinsic ion channels are the fastest acting transduction mechanisms. These receptors, also known as ligand-gated ion channels (LGICs), allow for immediate ion flux upon ligand binding, leading to rapid cellular responses. Examples include nicotinic acetylcholine receptors (nAChR), GABA_A receptors, and NMDA receptors. When a neurotransmitter binds, the ion channel opens within milliseconds, allowing ions (e.g., Na+, K+, Cl-, or Ca2+) to flow across the membrane. This results in rapid depolarization or hyperpolarization, leading to an immediate effect, such as muscle contraction (nAChR) or inhibitory neuronal signaling (GABA_A receptors). Due to their speed (milliseconds), intrinsic ion channels are the fastest transduction mechanism, making option A the correct answer. Incorrect Options: B) Adenylyl cyclase-cyclic AMP pathway – Incorrect This pathway involves G-protein-coupled receptors (GPCRs), which activate adenylyl cyclase (AC) to produce cyclic AMP (cAMP). cAMP then activates protein kinase A (PKA), leading to phosphorylation of target proteins and cellular responses. Although relatively fast, GPCR signaling takes seconds to minutes, making it slower than intrinsic ion channels. C) Phospholipase C-IP3/DAG pathway – Incorrect This pathway is also G-protein-mediated (GPCRs) and involves phospholipase C (PLC) activation, which generates IP3 (inositol trisphosphate) and DAG (diacylglycerol). IP3 releases intracellular Ca2+, and DAG activates protein kinase C (PKC), leading to cellular responses. This pathway typically acts within seconds to minutes, slower than ion channels. D) Nuclear receptor – Incorrect Nuclear receptors, such as those for steroids (e.g., cortisol, estrogen, and thyroid hormones), are located intracellularly and act by regulating gene transcription. When a ligand binds, the receptor-ligand complex enters the nucleus, binds to DNA, and alters gene expression. Since this process requires transcription and protein synthesis, it is very slow (hours to days), making it the slowest of all options.",
      "correct_choice_id": 277129,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31094901700310507/31094901700310507.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31094901700310507/31094901700310507.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66330,
      "choices": [
        {
          "id": 277133,
          "text": "Pharmacologic antagonist"
        },
        {
          "id": 277134,
          "text": "Physiologic antagonist"
        },
        {
          "id": 277135,
          "text": "Partial agonist"
        },
        {
          "id": 277136,
          "text": "Chemical antagonist"
        }
      ],
      "text": "Which of the following terms best describes the antagonism of leukotrienes’ Broncho constrictor effect (mediated at the leukotriene receptors) by terbutaline (acting at the adrenoceptor) in a patient with asthma",
      "unique_key": "Q9101745",
      "question_audio": null,
      "question_video": null,
      "map_id": 34131117,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Physiologic Antagonist Physiologic antagonism occurs when two drugs produce opposing effects through different receptors or mechanisms. In this case: Leukotrienes cause bronchoconstriction by acting on leukotriene receptors in the airway smooth muscles, worsening asthma symptoms. Terbutaline, a β2-adrenergic agonist, relaxes bronchial smooth muscles by stimulating β2-adrenoceptors, leading to bronchodilation. Since terbutaline counteracts the effects of leukotrienes through a different receptor system, this is an example of physiologic antagonism. Incorrect Options: A) Pharmacologic antagonist – Incorrect A pharmacologic antagonist directly competes for the same receptor as the agonist, preventing its activation. Example: Montelukast, a leukotriene receptor blocker, is a pharmacologic antagonist because it binds to leukotriene receptors and prevents leukotriene action. Terbutaline does not act on leukotriene receptors but instead works on β2-adrenoceptors, making this option incorrect. C) Partial agonist – Incorrect A partial agonist activates the same receptor as the full agonist but produces a weaker response. Example: Buprenorphine is a partial agonist at opioid receptors. Since terbutaline does not act on leukotriene receptors at all, it is not a partial agonist. D) Chemical antagonist – Incorrect A chemical antagonist directly interacts with the agonist itself (not its receptor) to neutralize or inactivate it. Example: Protamine sulfate neutralizing heparin in cases of heparin overdose. Terbutaline does not chemically inactivate leukotrienes; it opposes their effects via different receptors, so this is incorrect.",
      "correct_choice_id": 277134,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12073141700310553/12073141700310553.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12073141700310553/12073141700310553.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66331,
      "choices": [
        {
          "id": 277137,
          "text": "Chronic administration of phenobarbital with the drug"
        },
        {
          "id": 277138,
          "text": "Displacement from tissues binding sites by another drug"
        },
        {
          "id": 277139,
          "text": "Chronic administration of rifampicin"
        },
        {
          "id": 277140,
          "text": "Chronic administration of cimetidine with the drug"
        }
      ],
      "text": "A factor that is likely to increase the duration of action of a drug D that is partially metabolized by CYP3A4 in the liver is:",
      "unique_key": "Q9961340",
      "question_audio": null,
      "question_video": null,
      "map_id": 34398998,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Chronic administration of cimetidine with the drug Cimetidine is a potent inhibitor of CYP3A4, a key enzyme involved in the metabolism of many drugs, including drug D. When cimetidine is administered chronically, it inhibits the metabolism of drug D, leading to reduced clearance and prolonged duration of action. Since drug D is only partially metabolized by CYP3A4, this inhibition can significantly slow its elimination, causing higher plasma levels and prolonged therapeutic (or toxic) effects. Incorrect Options: (A) Chronic administration of phenobarbital with the drug – Incorrect Phenobarbital is a CYP3A4 inducer, meaning it increases the metabolism of drugs processed by this enzyme. This would lead to a faster clearance of drug D, reducing its plasma concentration and shortening its duration of action. Since the question asks for a factor that increases drug D’s duration, this is incorrect. (B) Displacement from tissue binding sites by another drug – Incorrect Displacement of drug D from tissue binding sites might increase its free plasma concentration initially, but this usually leads to faster metabolism and elimination rather than prolonged action. In most cases, displacement effects are transient and do not significantly extend the drug’s duration. (C) Chronic administration of rifampicin – Incorrect Rifampicin is a strong inducer of CYP3A4, meaning it accelerates the metabolism of drug D, leading to faster clearance and shorter duration of action. Since this has the opposite effect of prolonging the drug’s duration, this answer is incorrect.",
      "correct_choice_id": 277140,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7728261700310731/7728261700310731.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7728261700310731/7728261700310731.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66332,
      "choices": [
        {
          "id": 277141,
          "text": "Glucuronidation"
        },
        {
          "id": 277142,
          "text": "Oxidation"
        },
        {
          "id": 277143,
          "text": "Reduction"
        },
        {
          "id": 277144,
          "text": "Acetylation"
        }
      ],
      "text": "All of the following reactions are catalyzed by microsomal enzymes EXCEPT:",
      "unique_key": "Q9448046",
      "question_audio": null,
      "question_video": null,
      "map_id": 34262793,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Acetylation Acetylation is a phase II metabolic reaction that is primarily catalyzed by cytosolic enzymes, specifically N-acetyltransferases (NATs). These enzymes are located in the cytoplasm, not in the microsomal (smooth endoplasmic reticulum) enzyme system. Acetylation is important in the metabolism of drugs like isoniazid, sulfonamides, hydralazine, and procainamide, and individuals can be classified as slow or fast acetylators based on genetic variation. Incorrect Options: (A) Glucuronidation – Incorrect Glucuronidation is a phase II conjugation reaction that occurs in the microsomal system, specifically involving UDP-glucuronosyltransferases (UGTs). It plays a crucial role in drug detoxification and elimination, making drugs more water-soluble for renal or biliary excretion. Examples include the metabolism of bilirubin, morphine, and acetaminophen. (B) Oxidation – Incorrect Oxidation is a phase I metabolic reaction predominantly catalyzed by cytochrome P450 (CYP) enzymes, which are part of the microsomal enzyme system in the smooth ER. This reaction introduces oxygen atoms into the drug molecule, making it more polar and easier to be excreted or further metabolized. Examples include the metabolism of benzodiazepines, warfarin, and propranolol. (C) Reduction – Incorrect Reduction is another phase I metabolic reaction that occurs within the microsomal enzyme system and is facilitated by reductases. It involves the gain of electrons (or hydrogen atoms), often leading to the activation or inactivation of drugs. Examples include the metabolism of chloramphenicol and nitro-containing drugs like nitrazepam.",
      "correct_choice_id": 277144,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23366911700310773/23366911700310773.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23366911700310773/23366911700310773.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66333,
      "choices": [
        {
          "id": 277145,
          "text": "Agonist"
        },
        {
          "id": 277146,
          "text": "Inverse Agonist"
        },
        {
          "id": 277147,
          "text": "Competitive Antagonist"
        },
        {
          "id": 277148,
          "text": "Partial Agonist"
        }
      ],
      "text": "A drug Z has affinity and intrinsic activity of 0.8, then it is a",
      "unique_key": "Q5215068",
      "question_audio": null,
      "question_video": null,
      "map_id": 34874358,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Partial Agonist A partial agonist is a drug that has affinity for a receptor and some intrinsic activity, but not maximal activity compared to a full agonist. Intrinsic activity refers to the ability of a drug to activate a receptor and produce a response, measured on a scale from 0 to 1: Full agonists have an intrinsic activity of 1 (maximal response). Partial agonists have an intrinsic activity between 0 and 1 (e.g., 0.8 in this case), meaning they activate the receptor but produce a submaximal response compared to full agonists. Example: Buprenorphine (a partial agonist of opioid receptors) provides analgesia but with a lower risk of respiratory depression than full agonists like morphine. Incorrect Options: (A) Agonist – Incorrect A full agonist has intrinsic activity = 1, meaning it produces the maximum possible response when binding to the receptor. Since drug Z has an intrinsic activity of 0.8 (less than 1), it does not qualify as a full agonist. (B) Inverse Agonist – Incorrect An inverse agonist has negative intrinsic activity (< 0, typically -1 to 0), meaning it reduces basal receptor activity instead of activating it. Since drug Z has intrinsic activity of 0.8 (positive), it cannot be an inverse agonist. (C) Competitive Antagonist – Incorrect A competitive antagonist has affinity but no intrinsic activity (0) because it binds to the receptor but does not activate it, instead blocking agonist binding. Since drug Z has intrinsic activity of 0.8, it is not an antagonist.",
      "correct_choice_id": 277148,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57482241700311182/57482241700311182.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57482241700311182/57482241700311182.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66334,
      "choices": [
        {
          "id": 277149,
          "text": "Human therapeutic exploratory study"
        },
        {
          "id": 277150,
          "text": "Human safety pharmacology study"
        },
        {
          "id": 277151,
          "text": "Human therapeutic confirmatory study"
        },
        {
          "id": 277152,
          "text": "Human micro dosing study"
        }
      ],
      "text": "Which of the following studies in clinical trial is done mainly for pharmacokinetic profile of drug using < 100 microgram of drug",
      "unique_key": "Q7044720",
      "question_audio": null,
      "question_video": null,
      "map_id": 34415487,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Human Microdosing Study A human microdosing study is a phase 0 clinical trial designed to assess the pharmacokinetic profile of a drug using very small doses, typically less than 100 micrograms. This dose is too low to cause any pharmacological effect but is sufficient to study absorption, distribution, metabolism, and excretion (ADME) of the drug. Microdosing studies help in early decision-making regarding whether to proceed with further clinical trials. These studies are useful for identifying promising drug candidates while minimizing risk and cost. They often use radiolabeled compounds and highly sensitive analytical techniques such as accelerator mass spectrometry (AMS). Incorrect Options: (A) Human Therapeutic Exploratory Study – Incorrect This corresponds to Phase I clinical trials, where a drug is tested in small groups of healthy volunteers to evaluate safety, tolerability, and dosage range. Unlike microdosing studies, higher doses are used in Phase I trials, and both pharmacokinetics and pharmacodynamics are assessed. (B) Human Safety Pharmacology Study – Incorrect These studies focus on evaluating potential adverse effects of the drug on major organ systems, such as the cardiovascular, respiratory, and central nervous systems. They involve larger doses than microdosing studies and aim to assess the safety profile, not just pharmacokinetics. (C) Human Therapeutic Confirmatory Study – Incorrect This corresponds to Phase III clinical trials, where the drug is tested on a large number of patients to confirm its efficacy, safety, and therapeutic benefits compared to existing treatments. It involves therapeutic doses and not microdoses used in pharmacokinetic studies.",
      "correct_choice_id": 277152,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34435221700311196/34435221700311196.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34435221700311196/34435221700311196.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66335,
      "choices": [
        {
          "id": 277153,
          "text": "Always precedes phase II metabolism"
        },
        {
          "id": 277154,
          "text": "Are carried out largely in the plasma"
        },
        {
          "id": 277155,
          "text": "Examples are oxidation and reduction reactions"
        },
        {
          "id": 277156,
          "text": "Includes such reactions as glucuronidation and sulfation"
        }
      ],
      "text": "A 46-year-old alcoholic male consumes a 7 peg of vodka 30 ml each before going to bed. After being absorbed from his gut, blood carries the alcohol through the portal vein into the liver where it can be metabolized. Phase I metabolism of ethanol is carried out by cytochrome P450 2E1. Which of the following is true of phase I metabolism?",
      "unique_key": "Q3538707",
      "question_audio": null,
      "question_video": null,
      "map_id": 34936499,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Examples are oxidation and reduction reactions Explanation for the Correct Answer: Phase I metabolism involves functionalization reactions such as oxidation, reduction, and hydrolysis, primarily catalyzed by the cytochrome P450 enzyme system (CYP450) in the liver. In the case of ethanol metabolism, CYP2E1 plays a major role in oxidation. Oxidation reactions introduce or expose a polar functional group (e.g., hydroxyl, carboxyl) to increase drug solubility. Reduction reactions involve the gain of electrons, which can also increase drug solubility and alter the chemical structure for further metabolism. Hydrolysis reactions break down molecules using water. In ethanol metabolism: Alcohol dehydrogenase (ADH) and CYP2E1 catalyze the oxidation of ethanol to acetaldehyde. Acetaldehyde is then further oxidized by aldehyde dehydrogenase (ALDH) to acetic acid, which is ultimately metabolized into carbon dioxide and water. Thus, option (C) is correct because Phase I metabolism primarily involves oxidation and reduction reactions. Explanation for the Incorrect Answers: (A) Always precedes phase II metabolism Incorrect, because Phase I metabolism does not always precede Phase II. Some drugs can undergo Phase II metabolism (conjugation) directly without requiring Phase I modification. Example: Morphine and acetaminophen can be directly glucuronidated without Phase I processing. (B) Are carried out largely in the plasma Incorrect, because Phase I metabolism primarily occurs in the liver, where the cytochrome P450 enzyme system is abundant. Although some drug metabolism can occur in the plasma, lungs, kidneys, and intestines, the major site of Phase I metabolism is the liver. (D) Includes such reactions as glucuronidation and sulfation Incorrect, because glucuronidation and sulfation are Phase II metabolism reactions, not Phase I. Phase II metabolism involves conjugation reactions that attach hydrophilic groups (e.g., glucuronic acid, sulfate, methyl groups) to drugs, making them more water-soluble for excretion.",
      "correct_choice_id": 277155,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21170791700304879/21170791700304879.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21170791700304879/21170791700304879.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66336,
      "choices": [
        {
          "id": 277157,
          "text": "Hydroxylated in the kidney"
        },
        {
          "id": 277158,
          "text": "Metabolized by sulfation"
        },
        {
          "id": 277159,
          "text": "Metabolites excreted in the urine"
        },
        {
          "id": 277160,
          "text": "Reabsorption occurs in the lungs"
        }
      ],
      "text": "A 78-year-old woman with vaginal vault stenosis and urinary burning is prescribed topical estrogen, which is applied to the anterior vaginal wall every other day. Physical examination reveals a mild cystocele. Which of the following statements is correct about this agent?",
      "unique_key": "Q7690876",
      "question_audio": null,
      "question_video": null,
      "map_id": 34688596,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Metabolized by sulfation Explanation for the Correct Answer: Topical estrogen therapy is commonly prescribed for vaginal atrophy, urinary symptoms, and vaginal vault stenosis in postmenopausal women. Estrogens undergo extensive metabolism in the liver, where they are primarily conjugated via sulfation and glucuronidation before excretion. Sulfation (Phase II metabolism) occurs in the liver and intestines, making estrogens more water-soluble for renal or biliary excretion. Sulfated estrogen metabolites can be hydrolyzed back into active estrogen forms in the gut via enterohepatic circulation, prolonging their effects. Thus, option (B) is correct because sulfation is a key metabolic pathway for estrogen metabolism. Explanation for the Incorrect Answers: (A) Hydroxylated in the kidney Incorrect, because estrogens are primarily hydroxylated in the liver, not the kidney. The cytochrome P450 enzymes (CYP1A2, CYP3A4) in the liver hydroxylate estrogens to form estrone and estradiol metabolites, which are then conjugated for excretion. (C) Metabolites excreted in the urine Partially correct but not the best answer. While estrogen metabolites are excreted in urine, the primary metabolic pathway is sulfation, which occurs before excretion. Therefore, sulfation (B) is the more fundamental metabolic step than simple urinary excretion. (D) Reabsorption occurs in the lungs Incorrect, because estrogens are not significantly reabsorbed in the lungs. While some drugs can undergo pulmonary circulation and metabolism, estrogens mainly undergo enterohepatic recirculation in the liver and intestines, not the lungs.",
      "correct_choice_id": 277158,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13578951700304898/13578951700304898.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13578951700304898/13578951700304898.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66337,
      "choices": [
        {
          "id": 277161,
          "text": "Morphine"
        },
        {
          "id": 277162,
          "text": "Naloxone"
        },
        {
          "id": 277163,
          "text": "Diazepam"
        },
        {
          "id": 277164,
          "text": "Propranolol"
        }
      ],
      "text": "Which of the following drugs is an example of a competitive antagonist?",
      "unique_key": "Q5144304",
      "question_audio": null,
      "question_video": null,
      "map_id": 34060566,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Naloxone. Naloxone is a competitive antagonist at opioid receptors (primarily the mu-opioid receptor), meaning it competes with opioid agonists like morphine or heroin for the same binding site. By blocking opioid receptors without activating them, naloxone rapidly reverses the effects of opioids, including respiratory depression, sedation, and euphoria. Because naloxone competes directly with opioids but does not activate the receptor, it can displace opioids from the receptor site, making it highly effective in opioid overdose reversal. Since competitive antagonism is characterized by reversible binding, increasing the concentration of the agonist (e.g., morphine) can overcome the effects of the antagonist (naloxone), which is a key feature of competitive inhibition. Explanation of Incorrect Options: (A) Morphine – Morphine is an opioid agonist, not an antagonist. It binds to and activates mu-opioid receptors, leading to analgesia, euphoria, and respiratory depression. Since it enhances receptor activation rather than blocking it, it is not an example of a competitive antagonist. (C) Diazepam – Diazepam is a benzodiazepine agonist that binds to GABA-A receptors, enhancing the inhibitory effects of GABA and producing sedation, muscle relaxation, and anxiolysis. It does not function as an antagonist but rather as a positive allosteric modulator, meaning it increases the receptor’s response to GABA rather than competing for the same active site. (D) Propranolol – Propranolol is a non-selective beta-blocker (β-adrenergic antagonist) that blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate and blood pressure. While propranolol is an antagonist, it acts more like a non-competitive or reversible antagonist depending on the situation, as it does not always allow for simple competition at the receptor level like naloxone does at opioid receptors.",
      "correct_choice_id": 277162,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54875921727531889/54875921727531889.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54875921727531889/54875921727531889.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66338,
      "choices": [
        {
          "id": 277165,
          "text": "Antagonistic interaction"
        },
        {
          "id": 277166,
          "text": "Synergistic interaction"
        },
        {
          "id": 277167,
          "text": "Additive interaction"
        },
        {
          "id": 277168,
          "text": "Inhibitory interaction"
        }
      ],
      "text": "What type of drug interaction occurs when two drugs produce an effect greater than the sum of their individual effects?",
      "unique_key": "Q1397011",
      "question_audio": null,
      "question_video": null,
      "map_id": 34808517,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Synergistic interaction. A synergistic interaction occurs when two drugs produce a combined effect that is greater than the sum of their individual effects. This means that when both drugs are taken together, their effects are amplified beyond what would be expected if their effects were simply added together. This interaction is often beneficial in clinical practice, particularly in antibiotic therapy, pain management, and chemotherapy. For example: Antibiotic synergy: The combination of penicillin and aminoglycosides (e.g., ampicillin and gentamicin) is used to treat enterococcal infections more effectively than either drug alone. Pain management: The combination of opioids (e.g., morphine) and NSAIDs (e.g., ibuprofen) provides greater pain relief than either drug alone. Chemotherapy: Certain cancer drug combinations (e.g., cisplatin and paclitaxel) work together to enhance cell death more than either drug alone. Synergistic interactions are widely used in medicine to increase efficacy, reduce drug resistance, and lower individual drug dosages, thus minimizing side effects. Explanation of Incorrect Options: (A) Antagonistic interaction – An antagonistic interaction occurs when one drug reduces or blocks the effect of another drug. This is the opposite of synergy. For example, naloxone (opioid antagonist) blocks the effects of morphine, reversing opioid-induced respiratory depression. Other examples include beta-blockers (e.g., propranolol) counteracting beta-agonists (e.g., albuterol) used in asthma treatment. Since antagonism leads to a reduced or neutralized effect rather than an enhanced one, this option is incorrect. (C) Additive interaction – In an additive interaction, the combined effect of two drugs is equal to the sum of their individual effects (1 + 1 = 2). This differs from synergy, where the effect is greater than the sum of the two drugs (1 + 1 > 2). For example, aspirin and acetaminophen together provide pain relief that equals their combined individual effects but do not amplify each other’s actions beyond that. Since the question specifically asks about an effect greater than the sum, additive interaction is incorrect. (D) Inhibitory interaction – This is not a standard term in pharmacology. However, it could refer to cases where one drug inhibits the metabolism or action of another, leading to altered drug levels or reduced effects. This type of interaction is better classified under antagonism or pharmacokinetic inhibition (e.g., CYP enzyme inhibition). Since this does not describe an enhanced effect, this answer is incorrect.",
      "correct_choice_id": 277166,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52623591727531917/52623591727531917.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52623591727531917/52623591727531917.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66339,
      "choices": [
        {
          "id": 277169,
          "text": "A drug that blocks a receptor"
        },
        {
          "id": 277170,
          "text": "A drug that enhances the effect of an endogenous substance"
        },
        {
          "id": 277171,
          "text": "A drug that has no effect on a receptor"
        },
        {
          "id": 277172,
          "text": "A drug that initiates a biological response upon binding to a receptor"
        }
      ],
      "text": "In pharmacodynamics, what does the term \"agonist\" refer to?",
      "unique_key": "Q8342246",
      "question_audio": null,
      "question_video": null,
      "map_id": 34522947,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) A drug that initiates a biological response upon binding to a receptor. In pharmacodynamics, an agonist is a substance that binds to a specific receptor and activates it, leading to a biological response. Agonists mimic the action of endogenous (naturally occurring) substances, such as neurotransmitters or hormones, and enhance or trigger a physiological effect. For example, morphine is an opioid receptor agonist that binds to opioid receptors and produces pain relief. Similarly, adrenaline is an agonist for adrenergic receptors, stimulating the fight-or-flight response. Explanation of Incorrect Options: (A) A drug that blocks a receptor This is incorrect because a drug that blocks a receptor is called an antagonist, not an agonist. Antagonists bind to receptors but prevent activation by endogenous ligands or agonists, thereby inhibiting the biological response. An example is propranolol, a beta-blocker that prevents adrenaline from stimulating beta-adrenergic receptors. (B) A drug that enhances the effect of an endogenous substance While agonists can mimic endogenous substances, this answer is misleading because it suggests a drug only enhances an endogenous substance rather than directly activating the receptor. Some drugs, like allosteric modulators, enhance the effect of endogenous substances but do not directly initiate a response, making this an inaccurate definition of an agonist. (C) A drug that has no effect on a receptor This is incorrect because an agonist must bind to a receptor and produce a biological effect. A drug with no effect on a receptor would be considered inert or an inactive compound, which does not fit the definition of an agonist.",
      "correct_choice_id": 277172,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55916711727532010/55916711727532010.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55916711727532010/55916711727532010.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66340,
      "choices": [
        {
          "id": 277173,
          "text": "Synergistic interaction"
        },
        {
          "id": 277174,
          "text": "Additive interaction"
        },
        {
          "id": 277175,
          "text": "Antagonistic interaction"
        },
        {
          "id": 277176,
          "text": "Pharmacokinetic interaction"
        }
      ],
      "text": "What type of drug interaction occurs when two drugs produce opposite effects on the same physiological function?",
      "unique_key": "Q1413620",
      "question_audio": null,
      "question_video": null,
      "map_id": 34758506,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Antagonistic interaction. An antagonistic drug interaction occurs when two drugs produce opposite effects on the same physiological function, reducing or neutralizing each other’s effects. This can happen through different mechanisms: Pharmacodynamic antagonism – When drugs act on the same receptor or pathway but produce opposing effects. Example: Beta-blockers (e.g., propranolol) reduce heart rate, while beta-agonists (e.g., albuterol) increase it. Physiological antagonism – When drugs act on different receptors or systems but still counteract each other’s effects. Example: Insulin lowers blood sugar, while glucocorticoids (e.g., prednisone) increase blood sugar. Chemical antagonism – When drugs chemically neutralize each other. Example: Protamine sulfate neutralizes the anticoagulant effects of heparin. Explanation of Incorrect Options: (A) Synergistic interaction This is incorrect because a synergistic interaction occurs when two drugs enhance each other’s effects, leading to a greater combined effect than either drug alone. For example, alcohol and benzodiazepines both depress the central nervous system (CNS), leading to enhanced sedation and respiratory depression. In contrast, antagonistic interactions reduce each other’s effects. (B) Additive interaction This is incorrect because an additive interaction occurs when two drugs with similar effects combine to produce a response equal to the sum of their individual effects. For example, aspirin and acetaminophen together provide enhanced pain relief by working on different pathways, but they do not oppose each other’s effects. (D) Pharmacokinetic interaction This is incorrect because pharmacokinetic interactions involve changes in drug absorption, distribution, metabolism, or excretion, rather than opposing physiological effects. For example, rifampin induces liver enzymes that increase the metabolism of warfarin, reducing its anticoagulant effect—this is a pharmacokinetic interaction, not a direct physiological opposition.",
      "correct_choice_id": 277175,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34397571727532302/34397571727532302.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34397571727532302/34397571727532302.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66341,
      "choices": [
        {
          "id": 277177,
          "text": "The process by which a receptor becomes more sensitive to its ligand"
        },
        {
          "id": 277178,
          "text": "The temporary loss of receptor responsiveness due to prolonged exposure to a ligand"
        },
        {
          "id": 277179,
          "text": "The binding of an antagonist that prevents receptor activation"
        },
        {
          "id": 277180,
          "text": "The upregulation of receptor expression in response to low ligand levels"
        }
      ],
      "text": "What is desensitization in the context of receptor pharmacology?",
      "unique_key": "Q1396940",
      "question_audio": null,
      "question_video": null,
      "map_id": 34348151,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) The temporary loss of receptor responsiveness due to prolonged exposure to a ligand. Desensitization, also known as tachyphylaxis, occurs when a receptor becomes less responsive to stimulation after continuous or repeated exposure to an agonist. This is a protective mechanism to prevent overstimulation of a receptor system. Desensitization can occur through several mechanisms: Receptor phosphorylation – Many G-protein-coupled receptors (GPCRs) undergo phosphorylation by G-protein receptor kinases (GRKs), leading to the recruitment of beta-arrestins, which prevent further activation. Receptor internalization – Prolonged activation can cause receptors to be removed from the cell surface via endocytosis, reducing their availability. Receptor downregulation – In chronic exposure cases, receptors may be degraded or transcriptionally suppressed, leading to reduced receptor numbers. Example: Continuous exposure to beta-agonists (e.g., albuterol) in asthma treatment can lead to decreased responsiveness over time, necessitating higher doses or drug rotation. Explanation of Incorrect Options: (A) The process by which a receptor becomes more sensitive to its ligand This is incorrect because desensitization decreases receptor sensitivity, not increases it. Increased receptor sensitivity occurs in upregulation when receptor numbers or activity increase due to chronic antagonist exposure (e.g., beta-blocker withdrawal leading to receptor hypersensitivity). (C) The binding of an antagonist that prevents receptor activation This is incorrect because antagonists block receptors but do not cause desensitization. Desensitization results from prolonged agonist exposure, whereas an antagonist prevents receptor activation altogether. Example: Naloxone (opioid antagonist) blocks opioid receptors but does not desensitize them. (D) The upregulation of receptor expression in response to low ligand levels This is incorrect because upregulation refers to an increase in receptor numbers due to chronic low stimulation, which is the opposite of desensitization. Example: Prolonged beta-blocker use leads to beta-receptor upregulation, making sudden withdrawal dangerous due to increased sensitivity.",
      "correct_choice_id": 277178,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55070201727532368/55070201727532368.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55070201727532368/55070201727532368.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}